RenDu Bio (688193.SH) disclosed its semi-annual report for 2024, with the company achieving a revenue of 86.6802 million yuan for the reporting period, an increase of 8.31% year-on-year. The net income attributable to shareholders of the listed company was 4.3308 million yuan, turning losses into profits year-on-year. The net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.1434 million yuan. The basic earnings per share is 0.12 yuan/share. The company plans to distribute a cash dividend of 1.00 yuan (tax included) for every 10 shares.
仁度生物(688193.SH)：上半年净利润433.08万元，同比扭亏为盈
Rendu Biology (688193.SH): net income of 43.308 million yuan in the first half of the year, turning losses into profits year-on-year.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated